{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:58:51Z","timestamp":1781153931489,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Therapeutic Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.curtheres.2026.100821","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T15:44:18Z","timestamp":1768664658000},"page":"100821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["As-Needed Medication Use for Agitation Across Valproic Acid Formulations"],"prefix":"10.1016","volume":"104","author":[{"given":"Michael","family":"Ley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Tiefenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Kneebusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1674-4210","authenticated-orcid":false,"given":"Kelly C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.curtheres.2026.100821_bib0001","article-title":"Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder","volume":"2013","author":"Cipriani","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.curtheres.2026.100821_bib0002","series-title":"StatPearls","article-title":"Valproic acid","author":"Rahman","year":"2023"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100821_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.curtheres.2026.100821_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114051","article-title":"Valproate, divalproex, valpromide: are the differences in indications justified?","volume":"158","author":"Delage","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.curtheres.2026.100821_bib0005","article-title":"Recommendations: generalised anxiety disorder and panic disorder in adults: management","year":"2011","journal-title":"Guidance NICE"},{"issue":"Suppl 1","key":"10.1016\/j.curtheres.2026.100821_bib0006","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.4103\/0019-5545.196974","article-title":"Clinical practice guidelines for management of bipolar disorder","volume":"59","author":"Shah","year":"2017","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100821_bib0007","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: acute and long-term treatment of mixed states in bipolar disorder","volume":"19","author":"Grunze","year":"2018","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100821_bib0008","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4088\/JCP.v60n0405","article-title":"The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study","volume":"60","author":"Zarate","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100821_bib0009","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1176\/appi.ajp.162.2.330","article-title":"Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions","volume":"162","author":"Wassef","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.curtheres.2026.100821_bib0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eplepsyres.2006.11.005","article-title":"Distinct absorption characteristics of oral formulations of valproic acid\/divalproex available in the United States","volume":"73","author":"Dutta","year":"2007","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100821_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(02)00007-4","article-title":"Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers","volume":"49","author":"Dutta","year":"2002","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100821_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2710.2007.00876.x","article-title":"Divalproex sodium vs. valproic acid: drug utilization patterns, persistence rates and predictors of hospitalization among VA patients diagnosed with bipolar disorder","volume":"32","author":"Iqbal","year":"2007","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100821_bib0013","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1185\/030079907X210831","article-title":"Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder","volume":"23","author":"Schumock","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.curtheres.2026.100821_bib0014","first-page":"45","article-title":"Divalproex sodium versus valproic acid in hospital treatment of psychotic disorders","volume":"2","author":"Schwartz","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100821_bib0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/inm.12265","article-title":"Descriptive analysis of pro re nata medication use at a Canadian psychiatric hospital","volume":"26","author":"Martin","year":"2017","journal-title":"Int J Ment Health Nurs"},{"key":"10.1016\/j.curtheres.2026.100821_bib0016","unstructured":"Ansari A, Osser DN, Lai LS, Schoenfeld PM, Potts KC Pharmacologic approach to the psychiatric inpatient. Principles of Inpatient Psychiatry, 1e. Psychiatry Health Library. Accessed February 7, 2026. https:\/\/psychiatry.lwwhealthlibrary.com\/\/content.aspx?sectionid=203680935&bookid=2539."},{"issue":"2","key":"10.1016\/j.curtheres.2026.100821_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0269881107067242","article-title":"PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions","volume":"21","author":"Davies","year":"2007","journal-title":"J Psychopharmacol Oxf Engl"},{"issue":"4","key":"10.1016\/j.curtheres.2026.100821_bib0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/JCP.0000000000000132","article-title":"PRN (As-Needed) psychotropic medication use in borderline patients and other personality-disordered subjects over 14 years of prospective follow-up","volume":"34","author":"Martinho","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.curtheres.2026.100821_bib0019","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1747-597X-2-29","article-title":"The prevalence and significance of substance use disorders in bipolar type I and II disorder","volume":"2","author":"Cerullo","year":"2007","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"6","key":"10.1016\/j.curtheres.2026.100821_bib0020","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.3390\/ijerph19063512","article-title":"Predictors of employment status for persons with bipolar disorder","volume":"19","author":"Lu","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"8","key":"10.1016\/j.curtheres.2026.100821_bib0021","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/medicina55080403","article-title":"Suicide Risk in Bipolar disorder: a brief review","volume":"55","author":"Dome","year":"2019","journal-title":"Medicina (Mex)"},{"key":"10.1016\/j.curtheres.2026.100821_bib0022","unstructured":"Wy TJP, Saadabadi A Schizoaffective disorder. In: StatPearls. StatPearls Publishing; 2025. Accessed February 7, 2026. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541012\/."},{"issue":"1","key":"10.1016\/j.curtheres.2026.100821_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/acps.13762","article-title":"Dosing levelsof antipsychotics and mood stabilizers in bipolar disorder: a nationwide cohort study on relapse risk and treatment safety","volume":"151","author":"Lintunen","year":"2024","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.curtheres.2026.100821_bib0024","unstructured":"DailyMed - DEPAKOTE- divalproex sodium tablet, delayed release. Accessed February 7, 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=08a65cf4-7749-4ceb-6895-8f4805e2b01f."},{"issue":"8","key":"10.1016\/j.curtheres.2026.100821_bib0025","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1176\/appi.ajp.161.8.1324","article-title":"Gender differences in the prescribing of antipsychotic drugs","volume":"161","author":"Seeman","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100821_bib0026","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/molecules27010104","article-title":"Insights into structural modifications of valproic acid and their pharmacological profile","volume":"27","author":"Mishra","year":"2021","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.curtheres.2026.100821_bib0027","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/pcn.12056","article-title":"Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia","volume":"67","author":"Fujita","year":"2013","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.curtheres.2026.100821_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01958834","article-title":"PRN psychotropic drug use on a psychiatric unit","volume":"62","author":"Walker","year":"1991","journal-title":"Psychiatr Q"}],"container-title":["Current Therapeutic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011393X26000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:21:36Z","timestamp":1781151696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011393X26000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":28,"alternative-id":["S0011393X26000020"],"URL":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100821","relation":{},"ISSN":["0011-393X"],"issn-type":[{"value":"0011-393X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"As-Needed Medication Use for Agitation Across Valproic Acid Formulations","name":"articletitle","label":"Article Title"},{"value":"Current Therapeutic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.curtheres.2026.100821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100821"}}